NEW YORK (GenomeWeb News) – BioFocus will perform drug-candidate screening and related services for the CHDI Foundation's Huntington's disease drug development programs under a five-year collaboration agreement, BioFocus' parent company Galapagos said today.
BioFocus will be eligible for up to $41 million in research fees over the course of the collaboration, for which it will use its full range of integrated drug discovery services. These discovery efforts will include neuronal assay development, high-content screening, fragment-based screening, computational chemistry, protein crystallography, as well as studies involving pharmacokinetics, absorption, distribution, metabolism, and elimination.
This agreement continues and expands a collaboration between the UK-based company and the non-profit institution that started in 2005.
"We are confident that the next five years of this long-standing relationship with CHDI will be as productive as the first five," Galapagos CEO Onno van de Stolpe said in a statement.